Oral cancer chemoprevention: COX-2 inhibitor a covenant


  • Shashi Keshwar Department of Oral Pathology, College of Dental Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal http://orcid.org/0000-0003-3638-5849
  • Sonal Grover Department of Oral Pathology and Microbiology, Christian Dental College, Ludhiana, Punjab, India
  • Daya Shankar Primary Health Center, Parsa, Bihar, India
  • Deependra Prasad Sarraf Department of Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of Health Sciences, Dharan, Nepal




COX-2 inhibitor, Inflammation, Oral cancer


Oral cancer survival remains poor despite advancement in treatment modalities. In oral cancer and oral premalignant lesions, cyclooxygenase-2 (COX-2) is widely expressed and tends to be enhanced especially in high-risk oral lesions. Numerous researches suggests that the inflammation pathway of cyclooxygenase/prostaglandin E2 (PGE2) leads to the development and progression of a number of cancers, including oral squamous cell carcinoma (OSCC). With an emphasis on research data, this article discusses the relationship between inflammation and cancer, summarizes the use of anti-inflammatory agents COX-2 inhibitors for cancer chemoprevention and treatment, and explains the mechanisms underlying the anti-cancer effects of anti-inflammatory agents (COX-2 inhibitors).


Metrics Loading ...

Author Biography

Shashi Keshwar, Department of Oral Pathology, College of Dental Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal

Dr Shashi Keshwar, MDS
Assistant Professor, Department of oral pathology


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Global facts on tobacco or oral health. World Health Organization, Geneva, 2018. Available at: http://www.who.int/oral_health/publications/fact_sheet_tobacco/en/index1.html. Accessed on 22nd October, 2020.

Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological Typing of Cancer and Pre-cancer of the Oral Mucosa, Ed. 2, Berlin, Germany: Springer-Verlag. 1997;21-6.

Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90(20):1529-36.

Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90(21):1609-20.

Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342(26):1960-8.

Hawkey CJ. COX-2 inhibitor. Lancet. 1999;353(9149):307-14.

Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-52.

Goldstein JL, Silverstein FE, Agrawal NM. Reduced risk of upper gastrointestinal ulcer complications with Celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95(7):1681-90.

Noble SC, King DS, Olutade JI. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician. 2000;61(12):3669-76.

Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPA Rgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 2002;98(6):817-23.

Jackel EC, Raja S, Tan J, Das SK, Dey SK, Griod DA et al. Correlation of expression of cycloozygenase-2, vascular endothelial growth factor, peroxisome proliferators-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(10):1253-59.

Kawamori T, Rao CV, Seihbert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58(3):409-12.

Masterrer JL, Leahy KM, Koki AT, Zweifel BS. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306-11.

Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173-96.

Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):e1370.

Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as corrupted policemen in cancer-related inflammation. Adv Cancer Res. 2015;128:141-71.

Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.

Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA. 2012;109(38):15101-8.

Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015;39(11):1137-45.

Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-30.

Erovic BM, Pelzmann M, Turhani D, Pammer J, Niederberger V, Neuchrist C et al. Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003;123(8):950-3.

Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, de Abreu MC et al. Nuclear factor kappa B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol. 2013;17(1):45-50.

Shibata M, Kodani I, Osaki M, Araki K, Adachi H, Ryoke K. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol. 2005;41(3):304-12.

Seyedmajidi M, Shafaee S, Siadati S, Khorasani M, Bijani A, Ghasemi N. Cyclo-oxygenase-2 expression in oral squamous cell carcinoma. J Cancer Res Ther. 2014;10(4):1024-9.

Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto DJ, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 2010;46(12):880-7.

Yang SF, Chen MK, Hsieh YS, Chung TT, Hsieh YH, Lin CW, et al. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem. 2010;285(39):29808-16.

Byatnal AA, Byatnal A, Sen S, Guddattu V, Solomon MC. Cyclooxygenase-2-An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. Pathol Oncol Res. 2015;21(4):1123-31.

Pannone G, Sanguedolce F, De Maria S, Farina E, Lo Muzio L, Serpico R et al. Cyclooxygenase isozymes in oral squamous cell carcinoma: A real-time RT-PCR study with clinicopathological correlations. Int J Immunopathol Pharmacol. 2007;20(2):317-24.

Qian M, Qian D, Jing H, Li Y, Ma C, Zhou Y. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2014;32(4):1681-8.

Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcin. 1999;25(4):231-40.

Harris RE, Alshafie GA, Abou-Issa H. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60(8):2101-03.

Grabbs CJ, Lubet RA, Koki AT. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60(20):5599-602.

Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP et al. Cyclooxygenase-2 expression up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):9991-4.

Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev. 1994;13(3-4):303-8.

Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):705-16.

Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7(11):1163-70.

Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaranmaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract (review). Ann N Y Acad Sci. 2001;952:109-15.

Yamamoto K, Kitayama W, Denda A, Morisaki A, Kuniyasu H, Kirita T. Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide. Cancer Lett. 2003;199(2):121-9.

Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H et al. A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol. 2003;18(1):39-48.

Minter HA, Evesion JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase-2 selective inhibitor NS398 inhibits proliferation of oral carcinoma cells lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9(5):1885-97.

Tanaka T, Nishikawa A, Mori Y, Morishita Y, Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett. 1989;48(3):177-82.

Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell. 1995;83(3):493-501.

Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Investig. 1995;96(1):491-503.

Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferators-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol. Head Neck Surg. 2001;127(10):1253-9.

Gallo O, Franchi A, Magnelli L, Sardi L, Boddi V, Chiarugi V et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61.

Chen YJ, Jin YT, Shieh DB, Tsai ST, Wu L. W. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol. 2002;38(7):699-702.

Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cells. 1998; 93(5):705-15.

Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada L, Kitayama J et al. Inhibition of hematogenous metastasis of colon cancer in mice by a selective Cox-2 inhibitor, JTE522. Br J Cancer. 1999;81(8):1274-9.

Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cells. Laryngoscope. 2002;112(5):839-43.

Soh JW, Weinstein IB. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res. 2003;37:261-85.






Review Articles